{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:43:42Z","timestamp":1753875822132,"version":"3.41.2"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Assessing the frequency of ovarian metastasis from nonovarian cancer (N-OC) and evaluate whether any PET-derived parameters can distinguish metastasis from primary ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients undergoing FDG PET\/CT due to suspected ovarian malignancy from 2006 to 2021 with subsequent histologically proven ovarian metastasis from N-OC were included. Exclusion criteria included ovarian metastasis diagnosed prior to PET\/CT or &amp;gt;3\u2009months after. Baseline characteristics were collected from electronic medical records, and PET\/CT data were analysed using Siemens syngo.via software.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients (N =1502) were scanned for suspected ovarian malignancies. Sixty-five patients (4%) were included. The most common origin of metastases was lower gastrointestinal cancer (n\u2009=\u200929, 45%), followed by gynaecological cancer (n\u2009=\u200910, 15%) and breast cancer (n\u2009=\u20099, 14%). Among patients with previous cancer history (n\u2009=\u200926), 18 experienced ovarian metastases from a known cancer. Time from primary diagnosis to ovarian metastasis ranged from 47\u2009days to 11.4\u2009years. There were no differences in maximized standardized uptake value, peak standardized uptake value, or clinical parameters between ovarian metastases and primary ovarian tumours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The frequency of ovarian metastases from N-OCs was 4%, the most common origin of metastases was lower gastrointestinal tract. Previous cancer history is an important factor in assessing an unknown tumour of the ovary, as metastases can occur several years later. No PET or clinical parameters were useful for separating primary ovarian cancer from ovarian metastases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge<\/jats:title>\n                  <jats:p>The study finds a low frequency of ovarian metastasis from N-OC and indicates that no PET or clinical parameters can distinguish ovarian metastasis from primary ovarian cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjro\/tzaf004","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:57:56Z","timestamp":1742313476000},"source":"Crossref","is-referenced-by-count":0,"title":["The frequency and characterization of ovarian metastasis from nonovarian cancers using 18F-fluorodeoxyglucose PET\/CT"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-1424","authenticated-orcid":false,"given":"Nikoline D","family":"Fr\u00f8lich","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital , 9000 Aalborg,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-4785","authenticated-orcid":false,"given":"Jeannette D","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital , 9000 Aalborg,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-288X","authenticated-orcid":false,"given":"Helle D","family":"Zacho","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital , 9000 Aalborg,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aalborg University , 9000 Aalborg,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2025033001433024900_tzaf004-B1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"2025033001433024900_tzaf004-B2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/IGC.0b013e3181b33cce","article-title":"Secondary ovarian malignancies frequency, origin, and characteristics","volume":"19","author":"De Waal","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"2025033001433024900_tzaf004-B3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2005.09.046","article-title":"Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics","volume":"101","author":"Antila","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2025033001433024900_tzaf004-B4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0090-8258(03)00075-1","article-title":"Metastatic ovarian tumors: a review of 64 cases","volume":"89","author":"Yada-Hashimoto","year":"2003","journal-title":"Gynecol Oncol"},{"key":"2025033001433024900_tzaf004-B5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ygyno.2006.11.005","article-title":"Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer","volume":"105","author":"Sk\u00edrnisd\u00f3ttir","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2025033001433024900_tzaf004-B6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00428-015-1771-2","article-title":"A national population-based study provides insight in the origin of malignancies metastatic to the ovary","volume":"467","author":"Bruls","year":"2015","journal-title":"Virchows Archiv"},{"key":"2025033001433024900_tzaf004-B7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10585-017-9856-8","article-title":"The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review","volume":"34","author":"Kube\u010dek","year":"2017","journal-title":"Clin Exp Metastasis"},{"key":"2025033001433024900_tzaf004-B8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00432-015-1978-2","article-title":"F-18 FDG PET\/CT findings of metastatic ovarian tumors from gastrointestinal tract origin","volume":"141","author":"Park","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025033001433024900_tzaf004-B9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/IGC.0000000000000074","article-title":"Diagnostic value of preoperative SUVmax on FDG-PET\/CT for the detection of ovarian cancer","volume":"24","author":"Tanizaki","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"2025033001433024900_tzaf004-B10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/RLU.0000000000000667","article-title":"The performance of contrast-enhanced FDG PET\/CT for the differential diagnosis of unexpected ovarian mass lesions in patients with nongynecologic cancer","volume":"40","author":"Lee","year":"2015","journal-title":"Clin Nucl Med"},{"key":"2025033001433024900_tzaf004-B11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.crad.2010.09.018","article-title":"FDG PET\/CT features of ovarian metastasis","volume":"66","author":"Kitajima","year":"2011","journal-title":"Clin Radiol"},{"key":"2025033001433024900_tzaf004-B12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MNM.0b013e328345b339","article-title":"FDG-PET\/CT for diagnosis of primary ovarian cancer","volume":"32","author":"Kitajima","year":"2011","journal-title":"Nucl Med Commun"},{"key":"2025033001433024900_tzaf004-B13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/0284186X.2010.500296","article-title":"Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer","volume":"50","author":"Risum","year":"2011","journal-title":"Acta Oncol"},{"key":"2025033001433024900_tzaf004-B14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5001\/omj.2015.85","article-title":"Validity of cancer antigen-125 (CA-125) and risk of malignancy index (RMI) in the diagnosis of ovarian cancer","volume":"30","author":"Al-Musalhi","year":"2015","journal-title":"Oman Med J"},{"key":"2025033001433024900_tzaf004-B15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3892\/mco.2022.2551","article-title":"Diagnostic value of risk of malignancy index in the clinical evaluation of ovarian mass","volume":"17","author":"Huwidi","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"2025033001433024900_tzaf004-B16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13224-014-0609-1","article-title":"Risk of malignancy index (RMI) in evaluation of adnexal mass","volume":"65","author":"Javdekar","year":"2015","journal-title":"J Obstet Gynecol India"},{"key":"2025033001433024900_tzaf004-B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025033001433024900_tzaf004-B18","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1007\/s00259-023-06406-x","article-title":"International EANM-SNMMI-ISMRM consensus recommendation for PET\/MRI in oncology","volume":"50","author":"Veit-Haibach","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025033001433024900_tzaf004-B19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025033001433024900_tzaf004-B20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/j.semnuclmed.2021.06.006","article-title":"PET\/CT variants and pitfalls in gynecological cancers","volume":"51","author":"Dejanovic","year":"2021","journal-title":"Semin Nucl Med"},{"key":"2025033001433024900_tzaf004-B21","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.21037\/tcr-21-2609","article-title":"A systematic review and meta-analysis of indirect comparison between miRNA and ctDNA in diagnosis of epithelial ovarian cancer","volume":"10","author":"Fu","year":"2021","journal-title":"Transl Cancer Res"},{"key":"2025033001433024900_tzaf004-B22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12885-024-12461-w","article-title":"Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET\/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial","volume":"24","author":"Bentestuen","year":"2024","journal-title":"BMC Cancer"},{"key":"2025033001433024900_tzaf004-B23","first-page":"ijgc-2023-005264","article-title":"Patient satisfaction with ultrasound, whole-body CT and whole-body diffusion-weighted MRI for pre-operative ovarian cancer staging: a multicenter prospective cross-sectional survey","author":"Pinto","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"2025033001433024900_tzaf004-B24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13048-020-00714-8","article-title":"Ovarian metastasis from nongynecologic primary sites: a retrospective analysis of 177 cases and 13-year experience","volume":"13","author":"Zhang","year":"2020","journal-title":"J Ovarian Res"},{"key":"2025033001433024900_tzaf004-B25","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"2025033001433024900_tzaf004-B26","article-title":"CA 125 and epithelial ovarian cancer: role in screening, diagnosis, and Surveillance","author":"Pepin","year":"2014","journal-title":"Am J Hematol\/Oncol"},{"key":"2025033001433024900_tzaf004-B27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00259-004-1703-x","article-title":"Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers","volume":"32","author":"Nishizawa","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025033001433024900_tzaf004-B28","first-page":"266","article-title":"Even-Sapir E. Normal and abnormal 18 F-FDG endometrial and ovarian uptake in pre-and postmenopausal patients: assessment by PET\/CT","volume":"45","author":"Lerman","year":"2004","journal-title":"J Nucl Med"}],"container-title":["BJR|Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjro\/advance-article-pdf\/doi\/10.1093\/bjro\/tzaf004\/62444148\/tzaf004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/7\/1\/tzaf004\/62444148\/tzaf004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/7\/1\/tzaf004\/62444148\/tzaf004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T19:19:07Z","timestamp":1743448747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjro\/article\/doi\/10.1093\/bjro\/tzaf004\/8084855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bjro\/tzaf004","relation":{},"ISSN":["2513-9878"],"issn-type":[{"type":"electronic","value":"2513-9878"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,27]]},"article-number":"tzaf004"}}